JP2023524064A5 - - Google Patents
Info
- Publication number
- JP2023524064A5 JP2023524064A5 JP2022566323A JP2022566323A JP2023524064A5 JP 2023524064 A5 JP2023524064 A5 JP 2023524064A5 JP 2022566323 A JP2022566323 A JP 2022566323A JP 2022566323 A JP2022566323 A JP 2022566323A JP 2023524064 A5 JP2023524064 A5 JP 2023524064A5
- Authority
- JP
- Japan
- Prior art keywords
- clofazimine
- pharmaceutically acceptable
- inhalable
- composition according
- polymorph
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063018677P | 2020-05-01 | 2020-05-01 | |
| US63/018,677 | 2020-05-01 | ||
| PCT/US2021/030155 WO2021222740A1 (en) | 2020-05-01 | 2021-04-30 | Clofazimine composition and method for the treatment or prophylaxis of viral infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023524064A JP2023524064A (ja) | 2023-06-08 |
| JP2023524064A5 true JP2023524064A5 (OSRAM) | 2024-05-09 |
Family
ID=78332269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022566323A Pending JP2023524064A (ja) | 2020-05-01 | 2021-04-30 | ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230248722A1 (OSRAM) |
| EP (1) | EP4142691A4 (OSRAM) |
| JP (1) | JP2023524064A (OSRAM) |
| KR (1) | KR20230005937A (OSRAM) |
| CN (1) | CN115666510A (OSRAM) |
| AU (1) | AU2021263580A1 (OSRAM) |
| BR (1) | BR112022022081A2 (OSRAM) |
| CA (1) | CA3177438A1 (OSRAM) |
| WO (1) | WO2021222740A1 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024544075A (ja) * | 2021-11-30 | 2024-11-27 | マンカインド コーポレイション | ブルーリ潰瘍におけるマイコバクテリウム・ウルセランスの局所治療のための製剤及び方法 |
| WO2025091042A1 (en) * | 2023-10-27 | 2025-05-01 | Mannkind Corporation | Methods for treating non-tuberculous mycobacterial infection |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071127B2 (en) * | 2006-10-24 | 2011-12-06 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| SG10201507036TA (en) | 2008-06-13 | 2015-10-29 | Mannkind Corp | A dry powder inhaler and system for drug delivery |
| MX2012005090A (es) * | 2009-11-02 | 2012-06-19 | Mannkind Corp | Aparato y metodo para la criogranulacion de una composicion farmaceutica. |
| WO2014144895A1 (en) * | 2013-03-15 | 2014-09-18 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
| US9532986B2 (en) * | 2014-04-08 | 2017-01-03 | Aradigm Corporation | Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria |
| BR112017008220A2 (pt) * | 2014-10-24 | 2018-01-09 | Redhill Biopharma Ltd. | terapia para inibição de replicação do vírus de rna de filamento único |
| US20160220710A1 (en) * | 2015-01-30 | 2016-08-04 | The Regents Of The University Of Michigan | Compositions and methods for delivering pharmaceutical agents |
| CN108853106B (zh) | 2017-05-09 | 2021-02-02 | 中国食品药品检定研究院 | 亚胺吩嗪类化合物作为狂犬病病毒抑制剂的用途 |
| JP2020536123A (ja) | 2017-10-02 | 2020-12-10 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | クロファジミンの吸入可能な組成物およびその使用方法 |
| WO2019110099A1 (en) | 2017-12-06 | 2019-06-13 | Qrumpharma Inc. | Inhalable clofazimine formulation |
| WO2020040818A1 (en) | 2018-08-23 | 2020-02-27 | Qrumpharma Inc. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
-
2021
- 2021-04-30 CN CN202180031573.9A patent/CN115666510A/zh active Pending
- 2021-04-30 AU AU2021263580A patent/AU2021263580A1/en active Pending
- 2021-04-30 KR KR1020227041996A patent/KR20230005937A/ko active Pending
- 2021-04-30 US US17/996,706 patent/US20230248722A1/en active Pending
- 2021-04-30 EP EP21796019.4A patent/EP4142691A4/en active Pending
- 2021-04-30 BR BR112022022081A patent/BR112022022081A2/pt unknown
- 2021-04-30 JP JP2022566323A patent/JP2023524064A/ja active Pending
- 2021-04-30 CA CA3177438A patent/CA3177438A1/en active Pending
- 2021-04-30 WO PCT/US2021/030155 patent/WO2021222740A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111297838A (zh) | 一种抗病毒药物的吸入喷雾剂 | |
| JP2008536546A5 (OSRAM) | ||
| JP2014503598A5 (OSRAM) | ||
| CN102186458A (zh) | 治疗慢性阻塞性肺病及其它肺疾病的方法 | |
| US20160346246A1 (en) | Methods for the treatment of lung diseases with mast cell stabilizers | |
| JP2012526084A (ja) | 濃縮肥満細胞安定化用薬学的調合物 | |
| JP2002532520A (ja) | 気道病治療および気道用薬剤送達のための化合物および方法 | |
| CN102448438A (zh) | 抗流行性感冒调配物及方法 | |
| CN1115152C (zh) | 用尿苷三磷酸及相关化合物治疗支气管炎的方法 | |
| JP2008513445A (ja) | 吸入による送達で治療効果のある薬剤の許容性の改善方法 | |
| JP2013539784A (ja) | 嚢胞性線維症の吸入デヌホソルでの治療方法 | |
| JP2023524064A (ja) | ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法 | |
| JP2024531784A (ja) | トブラマイシン吸入溶液を含む薬学的組立品及びその使用 | |
| US20180110774A1 (en) | Compositions and methods for treatment of pulmonary hypertension | |
| CA2701388C (en) | Calcium glycerophosphate for treating and preventing respiratory diseases or conditions | |
| TW201016215A (en) | Compositions and uses of antiviral active pharmaceutical agents | |
| KR20230035518A (ko) | 선천적 면역 반응을 생성하기 위한 퀴닌과 그의 용도 | |
| US20220202700A1 (en) | Compositions for the treatment of viral pulmonary infections | |
| JPWO2017022814A1 (ja) | ネブライザー用組成物 | |
| NZ717528B2 (en) | Aerosol tyrosine kinase inhibitor compounds and uses thereof | |
| NZ717528A (en) | Aerosol tyrosine kinase inhibitor compounds and uses thereof | |
| TW202602487A (zh) | 呼吸系統疾病的治療與預防 | |
| US20220152157A1 (en) | Compositions for the treatment of viral pulmonary infections | |
| Challoner | Aerosol delivery of antibiotics | |
| Abdalaziz et al. | Formulation strategy for hydroxychloroquine as inhaler dosage from as a potential for COVID-19 treatment |